
FDA Approves Genetic Test for Opioid Use Disorder
In a groundbreaking development, the FDA has given the green light to AVERT-D, the first-ever genetic test that can help determine a person's increased risk of opioid use disorder. This test utilizes a simple cheek swab to analyze genetic markers associated with addiction in the brain's reward system. With approximately six million people in the United States aged 12 and older suffering from opioid use disorder, this announcement brings hope in the fight against this major public health crisis.